Free Research Reports on These Biotech Stocks -- Prothena, PTC Therapeutics, Pulmatrix, and Puma Biotech

Friday, April 13, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 13, 2018 /PRNewswire/ -- strives to bring the best free research to the investment community. 

Today we are offering reports on PRTA, PTCT, PULM, and PBYI which can be accessed for free by signing up to shifts focus on the Biotech space, which harnesses biological processes to create
technologies and products for a wide variety of challenges - from expanding crop sizes to treating disease. Stocks under evaluation this morning are: Prothena Corp. PLC (NASDAQ: PRTA), PTC Therapeutics Inc. (NASDAQ: PTCT), Pulmatrix Inc. (NASDAQ: PULM), and Puma Biotechnology Inc. (NASDAQ: PBYI). All you have to do is sign up today for this free limited time offer by clicking the link below.


Dun Laoghaire, Ireland headquartered Prothena Corp. PLC's stock finished Thursday's session 0.82% lower at $37.60 with a total trading volume of 264,886 shares. Over the last month, the Company's shares have advanced 8.70%. The stock is trading above its 50-day moving average by 6.83%. Moreover, shares of Prothena, which focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories, have a Relative Strength Index (RSI) of 53.01.  

On March 20th, 2018, Prothena announced a global collaboration with Celgene Corporation, through a subsidiary, to develop new therapies for a broad range of neurodegenerative diseases. The multi-year R&D collaboration is focused on three proteins implicated in the pathogenesis of several neurodegenerative diseases, including tau, TDP-43, and an undisclosed target. 

On April 05th, 2018, research firm Barclays reiterated its 'Overweight' rating on the Company's stock with a decrease of the target price from $70 a share to $50 a share. Get the full research report on PRTA for free by clicking below at:

PTC Therapeutics

Shares in South Plainfield, New Jersey headquartered PTC Therapeutics Inc. climbed 3.26%, ending yesterday's session at $27.56 with a total trading volume of 752,718 shares. The stock has surged 34.37% in the previous three months and 168.09% over the past year. The Company's shares are trading 2.26% above their 50-day moving average and 32.95% above their 200-day moving average. Moreover, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders, have an RSI of 50.51. 

On April 04th, 2018, research firm Barclays downgraded the Company's stock rating from 'Equal Weight' to 'Underweight' while revising its previous target price from $24 a share to $26 a share.

On April 09th, 2018, PTC Therapeutics announced that it will hold its R&D Day on April 17th, 2018, from 12:00 p.m. ET to 5:00 p.m. ET in New York City. Members of the senior management and research teams will provide a corporate update and in-depth reviews of the Company's commercial products, scientific platforms, and R&D programs. Find your free research report on PTCT at:


On Thursday, Lexington, Massachusetts headquartered Pulmatrix Inc.'s stock rose 1.52%, to close the day at $0.50. A total volume of 2.44 million shares was traded, which was above their three months average volume of 614,960 shares. The Company's shares are trading 59.84% below their 50-day moving average. Additionally, shares of Pulmatrix, which engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology, have an RSI of 16.21. Sign up today for the free research report on PULM at:

Puma Biotechnology

Shares in Los Angeles, California headquartered Puma Biotechnology Inc. ended the day 1.44% higher at $67.10. A total volume of 834,212 shares was traded. The stock has surged 85.62% over the past year. The Company's shares are trading below their 50-day moving average by 1.72%. Furthermore, shares of Puma Biotech, which focuses on the development and commercialization of products to enhance cancer care in the US, have an RSI of 49.30. 

On April 03rd, 2018, Puma Biotech and Pint Pharma International S.A. have entered into an agreement for the latter to commercialize NERLYNX® (neratinib) in Argentina, Brazil, Chile, Colombia, Mexico, and the rest of Latin America. Neratinib was approved by the US FDA in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. It is not approved currently for commercialization outside of the US. Wall St. Equities' research coverage also includes the downloadable free report on PBYI at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store